COPD: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)

  NCT05270525· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

• Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)

  NCT07867184· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

  NCT07907991· Boehringer Ingelheim· Source

• A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Hoffmann-La Roche· Source

• Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD

  NCT05572632· University of California, San Francisco· Source

• COPD Prevalence and Risk Factors Among Saudi Adults Over 18 in Taif

  NCT07886346· Taif University· Source

• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· UCB Biopharma SRL· Source

• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· AstraZeneca· Source

• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  NCT07190222· Sanofi· Source

• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 3
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Proteomics 1
• Metabolomics 2
• Mass Spectrometry 2
• Flow Cytometry 2
• Immunohistochemistry 4
• Magnetic Resonance Imaging 1
• Cohort Studies 47
• Genome-Wide Association Study 5

• Protective effect of total Saponins from American ginseng against cigarette smoke-induced COPD in mice based on integrated metabolomics and network pharmacology.

  Biomed Pharmacother, Mar 2022

• An Integrative Transcriptomic and Metabolomic Study Revealed That Melatonin Plays a Protective Role in Chronic Lung Inflammation by Reducing Necroptosis.

  Front Immunol, May 2021

See which targets of this disease your abstract mentions, and go to the people working on them.